Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an immune booster help chemotherapy fight metastatic breast cancer?

NCT ID NCT05747794

Terminated Disease control Sponsor: Immutep S.A.S. Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial tests whether adding an experimental immunotherapy called eftilagimod alpha to standard chemotherapy (paclitaxel) can help people with HER2-negative metastatic breast cancer live longer. The study first finds the best dose of eftilagimod alpha, then compares the combination against chemotherapy alone. Participants receive the treatment in two phases: chemo-immunotherapy followed by immunotherapy alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental immunotherapy called eftilagimod alpha combined with the chemotherapy paclitaxel
What this could lead to
If it works, this could offer a new treatment option that extends survival for people with metastatic breast cancer.
What could go wrong
This is an early-to-mid-stage trial, so the combination may not prove more effective than chemotherapy alone and could cause additional side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CARCINOMA

Contacts and locations

Locations

  • ARENSIA Exploratory Medicine LLC

    Tbilisi, Georgia

  • ARENSIA Exploratory Medicine Phase I Unit

    Chisinau, 2025, Moldova

  • AZ Sint-Jan Brugge Oostende av

    Bruges, Belgium

  • Carolina Blood and Cancer Care Associates

    Rock Hill, South Carolina, 29723, United States

  • Centre Hospitalier de l'Ardenne

    Libramont, 6800, Belgium

  • Clinique Saint-Pierre- Ottignies

    Ottignies-Louvain-la-Neuve, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, 1200, Belgium

  • Grand Hopital de Charleroi - Hopital Notre Dame

    Charleroi, 6000, Belgium

  • Hospital Clinic de Barcelona

    Barcelona, 08036, Spain

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, 14004, Spain

  • Hospital Universitario de Jaén

    Jaén, 23007, Spain

  • Institut Català d'Oncologia

    Badalona, 08916, Spain

  • Oncology Consultants

    Houston, Texas, 77024, United States

  • Parc Taulí Hospital Universitari

    Barcelona, 08208, Spain

  • START Madrid - FJD, Hospital Fundación Jiménez Diaz

    Madrid, 28040, Spain

  • The George Washington University Cancer Center

    Washington D.C., District of Columbia, 20037, United States

  • The Oncology Institute

    Whittier, California, 90602, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Unidad Ensayos Clínicos Oncología Fundació IRB Lleida

    Lleida, 25196, Spain

  • Universitair Ziekenhuizen Antwerpen

    Edegem, 2650, Belgium

  • VHIO - Hospital Vall d'Hebron

    Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.